News & Updates

Patient-reported outcomes (PROs) from the phase III MIRASOL trial underpin the potential of the antibody drug conjugate mirvetuximab soravtansine (MIRV) to improve health-related quality of life (HRQoL) in women with folate receptor-alpha positive platinum-resistant ovarian cancer (FRα-positive PROC) as opposed to investigator’s choice of chemotherapy.

Patients with type 2 diabetes (T2D) who received combined treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RA) and sodium-glucose cotransporter-2 inhibitors (SGLT-2i) have a much lower risk of major adverse cardiovascular events (MACE) and serious renal events than those treated with either drug class alone, suggests a recent study.

Men with prostate cancer who consume higher amounts of plant-based foods have a lower risk of cancer progression, as shown in a longitudinal observational cohort study.